Anti-OJ autoantibodies: Rare or underdetected?

Vulsteke, Jean‐Baptiste; Satoh, Minoru; Malyavantham, Kishore S.; Bossuyt, Xavier; Langhe, Ellen De; Mähler, Michael

doi:10.1016/j.autrev.2019.05.002

Cited by 57 publications

(55 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many ARS have been identified, including anti-Jo-1, PL-7, PL-12, EJ, OJ, ZO, and WRS. 13 In 1999, Hirakata et al reported that the same antibody was found in the serum of three patients named KS, KN, and NI. After further determination, it was identified as an antibody against asparaginyl tRNA, which was later uniformly designated "KS antibody."…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Anti-KS autoantibodies are rare myositis-specific autoantibodies that have been described to target asparaginyl-transfer RNA synthetase. Methods: Here, we review the published literature on critical issues concerning the detection of anti-KS antibodies and the clinical features associated with their presence. Results: Seven articles are reviewed, in all of which immunoprecipitation was employed for the detection of anti-KS antibodies. A total of 47 patients were included; the ratio of females to males was 1.9:1. In total, 46 (98%) of these patients had interstitial lung disease (ILD), which was the sole manifestation in half (50%) of them. Pulmonary pathology revealed 7 (27%) with usual interstitial pneumonia, and 16 (62%) with non-specific pneumonia. Arthritis was present in about one-quarter (26%) of patients, and the incidence of Raynaud’s phenomenon and mechanic’s hands was 19% and 32%, respectively. However, manifestations of myositis were rare (9%). In addition, three (11%) patients had malignant tumors. Most patients responded to glucocorticoid therapy. Conclusions: Identifying anti-KS in patients with ILD may be useful for treatment, but reliable practical detection is needed. Furthermore, clinicians need to be aware of the possible presence of anti-KS antibodies in patients with ILD, either isolated or in combination with myositis.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Many ARS have been identified, including anti-Jo-1, PL-7, PL-12, EJ, OJ, ZO, and WRS. 13 In 1999, Hirakata et al . reported that the same antibody was found in the serum of three patients named KS, KN, and NI.…”

Section: Discussionmentioning

confidence: 99%

Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Anti‐OJ and anti‐Th/To antibodies are rare and specific with polymyositis/dermatomyositis and systemic sclerosis (SSc), respectively 1,2 . We report a patient with SSc who subsequently developed polymyositis and fulminant cardiomyopathy, and had both anti‐OJ and anti‐Th/To antibodies.…”

Section: Figurementioning

confidence: 99%

Myocarditis in a patient with anti‐OJ and Th/To autoantibody‐positive overlap syndrome

Yonamine

Omine

Miyagi

et al. 2021

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

Anti‐OJ and anti‐Th/To antibodies are rare and specific antibodies that are seen in patients with polymyositis/dermatomyositis and systemic sclerosis (SSc), respectively. Anti‐Th/To antibody‐positive scleroderma is associated with severe pulmonary hypertension, interstitial pneumonia, and renal crisis, but is usually not complicated by myositis. Herein, we present the case of a patient with SSc who subsequently developed polymyositis and fulminant cardiomyopathy, and had both anti‐OJ and anti‐Th/To antibodies.

show abstract

“…Patients with anti-PL-12 may have increased rates of Raynaud’s phenomenon [52] and isolated ILD [52]. Conclusions about anti-OJ, anti-EJ, anti-KS, anti-Zo, and anti-Ha antibodies are harder to draw given the relative rarity of these antibodies, although more severe myopathy may be present in anti-OJ patients [61, 62].…”

Section: Myositis-ildmentioning

confidence: 99%

Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?

Soskis

Hallowell

2021

Respiration

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a cause of substantial morbidity and mortality amongst autoimmune diseases, including myositis. Despite first-line therapy with immunosuppression, many inflammatory ILDs advance to a fibrotic stage. In such patients, progressive fibrosis may be amenable to treatment with antifibrotic medications, which were initially studied and approved for the treatment of idiopathic pulmonary fibrosis. We here review the available data that support the use of antifibrotics in connective tissue diseases and progressive fibrosing ILDs. There is now a growing body of evidence in both large randomized clinical trials and on the evolving pathophysiologic pathways to support the use of antifibrotics in select patients with autoimmune ILD and a fibrotic phenotype. Further study of antifibrotics in combination with immunosuppressive medications, and in the myositis-ILD population, is needed.

show abstract

Anti-OJ autoantibodies: Rare or underdetected?

Cited by 57 publications

References 58 publications

Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome

Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome

Myocarditis in a patient with anti‐OJ and Th/To autoantibody‐positive overlap syndrome

Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?

Contact Info

Product

Resources

About